EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC 4.0

Ileal bile acid transporter inhibitors in Alagille syndrome and Progressive Familial Intrahepatic Cholestasis: A systematic review into dose–response

Alise D E de Groot iD, Cristina Chiadò, Jos G W Kosterink, Willem S Lexmond, Paola Mian iD, Henkjan J Verkade

British Journal of Clinical Pharmacology · 2026

DOI: 10.1002/bcp.70277 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Alise D E de Groot und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Pediatric Gastroenterology and Hepatology, University of Groningen, Beatrix Children's Hospital, University Med…. Hauptthemen laut MEDLINE: Alagille Syndrome, Cholestasis, Intrahepatic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ileal bile acid transporter inhibitors (IBATi), including maralixibat and odevixibat, are a novel approach to the treatment of paediatric cholestatic liver diseases, such as Alagille syndrome (ALGS) and different forms of progressive familial intrahepatic cholestasis (PFIC). Multiple phase 3 trials have demonstrated efficacy of IBATi in alleviating pruritus and decreasing serum bile acid (sBA) in a significant subset of patients. While most clinical IBATi trials included low‐dose and high‐dose treatment, a consistent dose–response effect has not been uniformly reported. This systematic review aims to assess the dose–response relationship for IBATi in patients with ALGS or PFIC, based on available pruritus, sBA and (non‐)responder outcomes, identifying minimally effective dosage and exploring the potential for personalized dosing strategies. A systematic search was conducted across PubMed, EMBASE, Web of Science and Cochrane Library of articles, oral presentations, posters presentations and abstracts up to 29 July 2024. The analysis included 75 records, of which 68 reported sBA and 63 reported pruritus outcomes. An evident dose–response relationship was not observed for either maralixibat or odevixibat in PFIC or ALGS. In the case of odevixibat, outcomes measures for patients with ALGS have only been reported for a dosage of 120 μg/kg/day. In conclusion, the variability in therapeutic outcomes of different doses for all IBATi underscores the necessity for personalization of dosing, which may include decreasing the dosage for responders to IBATi.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alagille SyndromeCholestasis, IntrahepaticHumansDose-Response Relationship, DrugBile Acids and SaltsPruritusTreatment OutcomeIleumDioxolanesCarrier ProteinsMembrane GlycoproteinsMethylaminesThiazepines

Stichwörter der Autor:innen

Alagille syndromedose–response relationshipgenetic cholestatic diseasesileal bile acid transporter inhibitorspaediatricprogressive familial intrahepatic cholestasis

Substanzen

Bile Acids and Salts3-((((3R,5R)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-yl)methyl)amino…bile acid binding proteinsDioxolanesCarrier ProteinsMembrane GlycoproteinsMethylaminesThiazepines

Autor:innen und Institutionen

  • Department of Pediatrics, Division of Pediatric Gastroenterology and Hepatology, University of Groningen, Beatrix Children's Hospital, University Medical Center Groningen, Groningen, The Netherlands.
  • University of Turin, Turin, Italy.
  • Pediatric Gastroenterology Unit, Regina Margherita Children's Hospital, Turin, Italy.
  • Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Research Institute of Pharmacy, Pharmacotherapy, Epidemiology & Economics, University of Groningen, Groningen, The Netherlands.
  • Department of Pediatrics, Beatrix Children's Hospital, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

ORCID-Profile: Alise D E de Groot, Paola Mian

Zitieren

APA

de Groot, A. D. E., Chiadò, C., Kosterink, J. G. W., Lexmond, W. S., Mian, P., & Verkade, H. J. (2026). Ileal bile acid transporter inhibitors in Alagille syndrome and Progressive Familial Intrahepatic Cholestasis: A systematic review into dose–response. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70277

Vancouver

de Groot ADE, Chiadò C, Kosterink JGW, Lexmond WS, Mian P, Verkade HJ. Ileal bile acid transporter inhibitors in Alagille syndrome and Progressive Familial Intrahepatic Cholestasis: A systematic review into dose–response. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70277

BibTeX
@article{deGroot2026,
  author = {de Groot, Alise D E and Chiadò, Cristina and Kosterink, Jos G W and Lexmond, Willem S and Mian, Paola and Verkade, Henkjan J},
  title = {Ileal bile acid transporter inhibitors in Alagille syndrome and Progressive Familial Intrahepatic Cholestasis: A systematic review into dose–response},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70277}
}
Kostenlos starten →